Intravenous Infusions (XGHA:IIL) Notes Receivable: GHS0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions Notes Receivable?

Intravenous Infusions XGHA:IIL +8.86% Notes Receivable is GHS0.00 Mil as of . 20.

Intravenous Infusions's Notes Receivable for the quarter that ended in . 20 was GHS0.00 Mil.

Intravenous Infusions Notes Receivable Related Terms

Intravenous Infusions Notes Receivable Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Notes Receivable Chart

Intravenous Infusions Annual Data
Trend
Notes Receivable

Intravenous Infusions Semi-Annual Data
Notes Receivable

Intravenous Infusions Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of GHS0.00 Mil mean?
Intravenous Infusions (XGHA:IIL) has a Notes Receivable of GHS0.00 Mil as of . 20. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Intravenous Infusions and its competitors.
Is Intravenous Infusions' Notes Receivable too high?
Intravenous Infusions' current Notes Receivable is GHS0.00 Mil.
How does Intravenous Infusions' Notes Receivable compare to PTLF and PCYN?
Intravenous Infusions' Notes Receivable of GHS0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Intravenous Infusions and its competitors. Intravenous Infusions's current Notes Receivable is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Notes Receivable of GHS0.00 Mil. The current Notes Receivable is GHS0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Notes Receivable is GHS0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.